GlassScriptPhysician profile
Melissa A Loftis
NPI 1619959814
$8,685.88
in general payments reported to CMS, 2019-2025
40 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,488 · 2022: $1,805 · 2023: $1,960 · 2024: $1,483 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,210 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,209.67 |
| Education | $184.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,459.77 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $893.27 | 2021-2025 | |
| Novo Nordisk INC | $865.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $677.99 | 2021-2025 | |
| Lilly USA, LLC | $632.87 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $619.91 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $405.13 | 2022-2025 | |
| Glaxosmithkline, LLC. | $335.43 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.51 | 2021-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Corium, LLC | $298.67 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $273.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $236.56 | 2021-2024 | Belsomra, Steglatro, Verquvo |
| Antares Pharma, INC. | $227.03 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $199.48 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $193.01 | 2023-2025 | Ajovy, Austedo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Loftis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.